Association Between Treatment Sequencing and Overall Survival in Stage IV NSCLC With Brain Metastases: A National Cancer Database Study
Thoracic Cancer · 2026-07 · 17 (14)
DOI: 10.1111/1759-7714.70359 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 19.07.2026. Verfasst von Anand Shah und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Rutgers New Jersey Medical, Newark, New Jersey, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The optimal sequencing of brain‐directed radiation and systemic therapy in stage IV non–small cell lung cancer (NSCLC) with brain metastases remains uncertain in the era of CNS‐active systemic agents. We evaluated survival outcomes using national real‐world data.
Methods
We conducted a retrospective cohort study of adults diagnosed between 2010 and 2022 with stage IV NSCLC and brain metastases in the National Cancer Database who received both brain‐directed radiation and systemic therapy. Treatment sequence was classified as radiation‐first or systemic‐first based on initiation dates. Multivariable Cox proportional hazards models, stratified by treatment era (pre‐2015 vs. 2015+), assessed associations with overall survival (OS), adjusting for demographic, clinical, tumor, and treatment factors. Propensity score matching and delayed‐entry sensitivity analyses were performed to address confounding and immortal time bias.
Results
Among 45 577 patients, 78.3% received radiation‐first and 21.7% received systemic therapy first. Unadjusted Kaplan–Meier analysis showed no significant difference in OS (log‐rank p = 0.624). In multivariable analysis, systemic‐first sequencing was associated with a modest increase in mortality (adjusted hazard ratio [aHR] 1.06; 95% CI: 1.04–1.09), which was consistent in propensity‐matched (HR 1.07; 95% CI: 1.04–1.11) and delayed‐entry analyses (aHR 1.09; 95% CI: 1.07–1.12). The use of systemic‐first therapy increased over time. Established prognostic factors demonstrated larger effect sizes.
Conclusion
Systemic‐first sequencing was associated with a modest increase in adjusted mortality; however, the effect size was small relative to established prognostic factors and likely influenced by residual confounding and selection bias. These findings support individualized, multidisciplinary treatment decisions rather than a uniform sequencing strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medicine, Rutgers New Jersey Medical, Newark, New Jersey, USA.
- Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Division of Hematology/Oncology, Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
- Rutgers Cancer Institute, Newark, New Jersey, USA.
ORCID-Profile: Anand Shah, Pranav Gwalani, Merry Zhai, Ritik Goyal, Joshua Kra
Zitieren
APA
Shah, A., Gwalani, P., Zhai, M., Goyal, R., & Kra, J. (2026). Association Between Treatment Sequencing and Overall Survival in Stage IV NSCLC With Brain Metastases: A National Cancer Database Study. Thoracic Cancer, 17(14). https://doi.org/10.1111/1759-7714.70359
Vancouver
Shah A, Gwalani P, Zhai M, Goyal R, Kra J. Association Between Treatment Sequencing and Overall Survival in Stage IV NSCLC With Brain Metastases: A National Cancer Database Study. Thoracic Cancer. 2026;17(14). doi:10.1111/1759-7714.70359
BibTeX
@article{Shah2026,
author = {Shah, Anand and Gwalani, Pranav and Zhai, Merry and Goyal, Ritik and Kra, Joshua},
title = {Association Between Treatment Sequencing and Overall Survival in Stage IV NSCLC With Brain Metastases: A National Cancer Database Study},
journal = {Thoracic Cancer},
year = {2026},
volume = {17},
number = {14},
doi = {10.1111/1759-7714.70359}
}
EUVIMED